Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| AAB-003 | PF-05236812 | Alzheimer's Disease (Discontinued) | Janssen, Pfizer | Amyloid-Related | Immunotherapy (passive) | |
| ABBV-916 | N3pG-Abeta mAb | Alzheimer's Disease (Phase 2) | Amyloid-Related | Immunotherapy (passive) | ||
| ADEL-Y01 | Alzheimer's Disease (Phase 1) | ADEL, Inc., Oscotec Inc. | Tau | Immunotherapy (passive) | ||
| Aduhelm | Aducanumab, BIIB037 |
Alzheimer's Disease (Approved) | Biogen, Neurimmune | Amyloid-Related | Immunotherapy (passive) | |
| AL002 | Alzheimer's Disease (Phase 2) | AbbVie, Alector | Inflammation | Immunotherapy (passive) | ||
| AL003 | Alzheimer's Disease (Discontinued) | AbbVie, Alector | Inflammation | Immunotherapy (passive) | ||
| AL044 | Alzheimer's Disease (Phase 1) | Alector | Inflammation | Immunotherapy (passive) | ||
| AL101 | GSK-4527226 | Alzheimer's Disease (Phase 2) | Alector, GlaxoSmithKline (GSK) | Other | Immunotherapy (passive) | |
| ANX005 | Amyotrophic Lateral Sclerosis (Phase 2) | Annexon, Inc. | Inflammation, Other | Immunotherapy (passive) | ||
| APNmAb005 | RAA7 | Alzheimer's Disease (Phase 1) | Aprinoia Therapeutics | Tau | Immunotherapy (passive) | |
| Bapineuzumab | AAB-001 | Alzheimer's Disease (Discontinued) | Janssen, Pfizer | Amyloid-Related | Immunotherapy (passive) | |
| Bepranemab | UCB0107 , UCB 0107 , Antibody D |
Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 2) | Hoffmann-La Roche, UCB S.A. | Tau | Immunotherapy (passive) | |
| BIIB076 | NI-105, 6C5 huIgG1/l |
Alzheimer's Disease (Discontinued) | Biogen, Eisai Co., Ltd., Neurimmune | Tau | Immunotherapy (passive) | |
| BMS-986446 | PRX005 | Alzheimer's Disease (Phase 2) | Bristol-Myers Squibb, Prothena | Tau | Immunotherapy (passive) | |
| Cinpanemab | BIIB054, NI-202 |
Parkinson's Disease (Discontinued) | Biogen, Neurimmune | alpha-synuclein | Immunotherapy (passive) | |
| Crenezumab | MABT5102A , RG7412 |
Alzheimer's Disease (Discontinued) | AC Immune SA, Genentech, Hoffmann-La Roche | Amyloid-Related | Immunotherapy (passive) | None |
| DNL919 | TAK-920, ATV:TREM2 |
Alzheimer's Disease (Discontinued) | Denali Therapeutics Inc., Takeda Pharmaceutical Company | Amyloid-Related, Inflammation | Immunotherapy (passive) | |
| Donanemab | N3pG-Aβ Monoclonal Antibody, LY3002813, Kisunla |
Alzheimer's Disease (Approved) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | |
| E2814 | Alzheimer's Disease (Phase 1/2) | Eisai Co., Ltd. | Tau | Immunotherapy (passive) | ||
| Etanercept | Enbrel™ | Alzheimer's Disease (Phase 2) | Amgen, Inc., Pfizer | Inflammation | Immunotherapy (passive) | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondilysis |
| Exidavnemab | BAN0805, ABBV-0805 |
Parkinson's Disease (Inactive) | AbbVie, BioArctic AB | alpha-synuclein | Immunotherapy (passive) | |
| Foralumab | TZLS-401, NI-0401, 28F11-AE |
Alzheimer's Disease (Phase 2) | Tiziana Life Sciences | Inflammation | Immunotherapy (passive) | |
| Gammagard® | Intravenous Immunoglobulin, IVIg |
Alzheimer's Disease (Discontinued) | Baxter Healthcare | Amyloid-Related, Inflammation | Immunotherapy (passive) | Immunodeficiency conditions |
| Gamunex | Intravenous Immunoglobulin, Human Albumin Combined With Flebogamma |
Alzheimer's Disease (Phase 2/3) | Grifols Biologicals Inc. | Amyloid-Related, Inflammation | Combination, Immunotherapy (passive) | Immunodeficiency, chronic inflammatory demyelinating neuropathy |
| Gantenerumab | RO4909832, RG1450, R1450 |
Alzheimer's Disease (Discontinued) | Chugai Pharmaceutical Co., Ltd., Hoffmann-La Roche | Amyloid-Related | Immunotherapy (passive) | |
| Gosuranemab | BIIB092, BMS-986168, IPN007 |
Progressive Supranuclear Palsy (Discontinued), Alzheimer's Disease (Discontinued) | Biogen, Bristol-Myers Squibb | Tau | Immunotherapy (passive) | |
| GSK933776 | Alzheimer's Disease (Inactive) | GlaxoSmithKline (GSK) | Amyloid-Related | Immunotherapy (passive) | ||
| IBC-Ab002 | Alzheimer's Disease (Phase 1) | ImmunoBrain Checkpoint | Amyloid-Related, Inflammation, Other | Immunotherapy (passive) | ||
| Latozinemab | AL001, GSK4527223 |
Frontotemporal Dementia (Phase 3), Amyotrophic Lateral Sclerosis (Inactive) | Alector, GlaxoSmithKline (GSK) | Other | Immunotherapy (passive) | |
| Leqembi | Lecanemab-irmb, BAN2401, mAb158 |
Alzheimer's Disease (Approved) | BioArctic AB, Biogen, Eisai Co., Ltd. | Amyloid-Related | Immunotherapy (passive) | |
| LU AF82422 | Parkinson's Disease (Phase 1), Multiple System Atrophy (Phase 2) | Genmab A/S, Lundbeck | alpha-synuclein | Immunotherapy (passive) | ||
| Lu AF87908 | hC10.2 | Alzheimer's Disease (Phase 1) | Lundbeck | Tau | Immunotherapy (passive) | |
| LY2599666 | Alzheimer's Disease (Discontinued) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | ||
| MEDI1814 | Alzheimer's Disease (Phase 1) | AstraZeneca, Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | ||
| MK-2214 | Alzheimer's Disease (Phase 1) | Merck | Tau | Immunotherapy (passive) | ||
| Octagam®10% | Intravenous Immunoglobulin, NewGam |
Alzheimer's Disease (Inactive), Mild Cognitive Impairment (Inactive) | Octapharma | Amyloid-Related, Inflammation | Immunotherapy (passive) | Immunodeficiency disorders |
| Pepinemab | VX15, VX15/2503 |
Alzheimer's Disease (Phase 1/2), Huntington's Disease (Phase 2) | Vaccinex, Inc. | Inflammation | Immunotherapy (passive) | |
| PMN310 | Alzheimer's Disease (Phase 1) | ProMIS Neurosciences, Inc. | Amyloid-Related | Immunotherapy (passive) | ||
| PNT001 | Alzheimer's Disease (Inactive), Traumatic Brain Injury (Inactive) | Pinteon Therapeutics | Tau | Immunotherapy (passive) | ||
| Ponezumab | PF-04360365 | Alzheimer's Disease (Discontinued), Cerebral Amyloid Angiopathy (Discontinued) | Pfizer | Amyloid-Related | Immunotherapy (passive) | None |
| Posdinemab | JNJ-63733657 | Mild AD (Phase 2) | Janssen | Tau | Immunotherapy (passive) | |
| Prasinezumab | PRX002, RO7046015, RG7935, NEOD002 | Parkinson's Disease (Phase 2) | Hoffmann-La Roche, Prothena | alpha-synuclein | Immunotherapy (passive) | |
| PRX012 | Alzheimer's Disease (Phase 1) | Prothena | Amyloid-Related | Immunotherapy (passive) | ||
| Remternetug | LY3372993, N3pG-Abeta mAb |
Alzheimer's Disease (Phase 3) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | |
| RG7345 | RO6926496 | Alzheimer's Disease (Discontinued) | Tau | Immunotherapy (passive) | ||
| Sabirnetug | ACU-193 | Alzheimer's Disease (Phase 2/3) | Acumen Pharmaceuticals, Inc. | Amyloid-Related | Immunotherapy (passive) | |
| SAR228810 | Alzheimer's Disease (Discontinued) | Sanofi | Amyloid-Related | Immunotherapy (passive) | ||
| Semorinemab | RO7105705 , MTAU9937A, RG6100 |
Alzheimer's Disease (Phase 2) | AC Immune SA, Genentech, Hoffmann-La Roche | Tau | Immunotherapy (passive) | |
| Solanezumab | LY2062430 | Alzheimer's Disease (Discontinued) | Eli Lilly & Co. | Amyloid-Related | Immunotherapy (passive) | None |
| TAK-341 | MEDI1341 | Parkinson's Disease (Phase 1), Multiple System Atrophy (Phase 2) | AstraZeneca, Takeda Pharmaceutical Company | alpha-synuclein | Immunotherapy (passive) | |
| TB006 | Alzheimer's Disease (Phase 1) | TrueBinding, Inc. | Inflammation | Immunotherapy (passive) | ||
| Tilavonemab | ABBV-8E12, C2N 8E12, HJ8.5 |
Progressive Supranuclear Palsy (Discontinued), Alzheimer's Disease (Discontinued) | AbbVie, C2N Diagnostics, LLC | Tau | Immunotherapy (passive) | |
| Trontinemab | RO7126209, RG6102 , Brain shuttle gantenerumab |
Alzheimer's Disease (Phase 1/2) | Hoffmann-La Roche | Amyloid-Related | Immunotherapy (passive) | |
| UCB7853 | Parkinson's Disease (Phase 1) | UCB S.A. | alpha-synuclein | Immunotherapy (passive) | ||
| VGL101 | Iluzanebart | Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (Phase 2) | Vigil Neuroscience, Inc. | Inflammation, Other | Immunotherapy (passive) | |
| VY-TAU01 | HC3LC2, Voyager_9 |
Alzheimer's Disease (Phase 1) | Voyager Therapeutics | Tau | Immunotherapy (passive) | |
| Zagotenemab | LY3303560 | Alzheimer's Disease (Discontinued) | Eli Lilly & Co. | Tau, Unknown | Immunotherapy (passive) |